Valaciclovir (ENT — Ramsay Hunt / Bell's Palsy)
Brand names: Valtrex
Valaciclovir is an oral prodrug of aciclovir, with better bioavailability, used for herpes simplex and varicella-zoster infections.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is converted to aciclovir, which after phosphorylation inhibits viral DNA polymerase and terminates the growing viral DNA chain, halting replication.
Prescribing in practice
- Reduce the dose in renal impairment and maintain adequate hydration, as accumulation can cause reversible neurotoxicity (confusion, agitation, hallucinations).
- Treatment is most effective when started early, ideally within the first days of symptom or rash onset, including in Ramsay Hunt syndrome and Bell's palsy.
- Higher antiviral doses are used for zoster than for simple herpes simplex; check current prescribing references for the indication.
Monitoring
Assess renal function in older patients and those with impairment, and watch for neurological symptoms that may indicate accumulation; ensure good fluid intake.
Counselling the patient
- Start treatment as soon as possible after symptoms begin for the best benefit.
- Drink plenty of fluids while taking it, particularly in older age.
- Report confusion, drowsiness or hallucinations, especially if you have kidney problems.
Evidence & guidelines
Improved oral bioavailability over aciclovir allows less frequent dosing; antivirals started early reduce the severity and duration of herpes zoster and are used adjunctively in facial nerve palsy per UK guidance.
Reference: Murakami et al. Ann Neurol 1997 (Ramsay Hunt); Engström et al. NEJM 2008 (Bell's palsy); NICE CG186; AAO-HNS Bell's Palsy Guidelines (2013); SIGN 120; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020